II. AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all previous listings.

1. (original) A compound of formula I

$$\begin{array}{c|c} & & & & \\ & & & \\ \hline \\ O & & \\ N & & \\ \end{array}$$

wherein R is (C_{1-40}) alkyl or (C_{1-40}) alkenyl, in free base or acid addition salt form.

2. (cancelled)

- 3. (currently amended) The compound of claim 1, wherein the compound is <u>useful</u> suitable for use as a pharmaceutical.
- 4. (currently amended) The compound of claim 1, wherein the compound is <u>useful</u> suitable for use in the treatment of a psychotic disorder.
- 5. (original) The compound of claim 4, wherein the psychotic disorder is selected from a group consisting of: schizophrenia and a bipolar disorder.
- 6. (cancelled)

7. (original) A method for the production of the compounds of formula I

$$\begin{array}{c|c} F & O \\ \hline \\ O & O \\ \hline \\ O & O \\ \hline \\ O & CH_3 \\ \hline \\ CH_3 & O \\ \hline \\ CH_3 & CH_3 \\ \hline \\ \end{array}$$

wherein R is (C_{1-40}) alkyl or (C_{1-40}) alkenyl, and their salts, the method comprising:

reacting a compound of formula II

with a compound of formula III

wherein R is (C_{1-40}) alkyl or (C_{1-40}) alkenyl and X is halogen; and recovering the resulting compound in free base or acid addition salt form.

8. (original) The method of claim 7, wherein the acid addition salt form includes a pharmaceutically acceptable acid addition salt form.

- 9. (currently amended) The method of claim 7, wherein the compound is <u>useful</u> suitable for use as a pharmaceutical.
- 10. (currently amended) The <u>method compound</u> of claim 7, wherein the compound is <u>useful</u> suitable for use in the treatment of a psychotic disorder.
- 11. (currently amended) The <u>method compound</u> of claim 10, wherein the psychotic disorder is selected from a group consisting of: schizophrenia and a bipolar disorder.
- 12. (currently amended) The <u>method</u> compound of claim 7, further comprising a pharmaceutical carrier or diluent.

13. (withdrawn) A method for the treatment of a psychotic disorder in a subject in need of such treatment, the method comprising:

administering to the subject a therapeutically effective amount of a compound of formula I

$$\begin{array}{c|c} & & & & \\ & & & \\ \hline \\ O & & \\ N & & \\ \hline \end{array}$$

wherein R is (C_{1-40}) alkyl or (C_{1-40}) alkenyl, in free base or pharmaceutically acceptable acid addition salt form.

- 14. (withdrawn) The method of claim 13, wherein administering includes at least one of the following: parenteral administration and transdermal administration.
- 15. (withdrawn) The method of claim 13, wherein an effective amount includes an amount between about 0.1 mg/kg and about 500 mg/kg of body weight of the subject.
- 16. (withdrawn) The method of claim 15, wherein an effective amount includes an amount between about 0.5 mg/kg and about 100 mg/kg of body weight of the subject.
- 17. (withdrawn) The method of claim 13, wherein the subject is a human.

- 18. (original) The method of claim 17, wherein an effective amount includes a daily dosage between about 10 mg and about 2000 mg.
- 19. (cancelled)
- 20. (withdrawn) The method of claim 13, wherein the compound of formula I is administered in a sustained release form.
- 21. (new) The compound of claim 1 in free base form.
- 22. (new) The compound of claim 1 in acid addition salt form, wherein the acid is a pharmaceutically acceptable acid.
- 23. (new) A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical carrier or diluent.